Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study Assessing EmSam in Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 18 - 65~2. DSM-IV Bipolar Disorder (I, II, NOS), Depressed Phase~3. DSM-IV Bipolar Disorder (I,II, NOS), Mixed state with adequate mood stabilization (ie, resolution of manic or hypomanic symptoms for 8 weeks with a minimum of 4 weeks on a stable dose of mood-stabilizing medication that will be continued through all phases of the study).~4. Prior failure of or inability to tolerate at least one other antidepressant treatment~5. Physically healthy~6. Agrees to participate in the study~7. HAM-D 24 \> 10~Exclusion Criteria:~1. Bipolar Disorder (I, II, NOS), Mixed State without adequate mood stabilization~2. Prior significant adverse reaction to EmSam~3. Unstable medical disorder~4. History of epilepsy (febrile seizure o.k.)~5. Current use of any medication that might interact with EnSam.~6. Use within 2 weeks of other antidepressant medication (6 weeks for fluoxetine)~7. Inability to adhere to a tyramine-free diet~8. Recent (past 6 months) suicide attempt~9. Serious suicidal ideation~10. Pregnant~11. Breast feeding~12. Fecund, sexually active females, without adequate contraception~13. Prior failure to respond to 2 or more adequate oral MAOI trials (2/3 PDR maximum dose, minimum 4 weeks)~14. Non-nicotine substance abuse/dependence within the past 6 months (1 year for amphetamines/cocaine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EmSam (Type: EXPERIMENTAL): EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).